Is there a correlation between -174(G/C) polymorphism of IL-6 gene and the incidence of acute myocardial infarction?
Cardiovascular disease
ELISA
Inflammation
SNP
Journal
Journal, genetic engineering & biotechnology
ISSN: 2090-5920
Titre abrégé: J Genet Eng Biotechnol
Pays: Netherlands
ID NLM: 101317150
Informations de publication
Date de publication:
20 Sep 2021
20 Sep 2021
Historique:
received:
18
06
2021
accepted:
05
09
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Cardiovascular disease (CVD) remains the major cause of death worldwide. Most CVD can be prevented by addressing risk factors. Acute myocardial infarction (AMI) is an inflammatory disorder characterized by changes in several cytokines including the interleukins (ILs). Studies are running to evaluate the genetic variation in the inflammatory system and their influence on the risk factors for CVD aiming for future prevention of this global disease. The aim of the current study was too investigate the association of -174 (G/C) IL-6 polymorphism with the incidence of AMI in a representative sector of the Egyptian population and to examine the contribution of IL-6, as a biomarker, in the pathogenesis of AMI. Genotyping of -174 (G/C) IL-6 polymorphism was done by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) while IL-6 levels were assayed by ELISA. The genotype distribution of -174 (G/C) IL-6 gene was not significantly different between the control subjects (GG 81.7%, GC 16.3%, CC 1.9%) and the AMI patients (GG 79%, GC 19%, CC 2%).The serum levels of IL-6 were significantly elevated in the AMI patients in comparison to the control subjects (P < 0.0001). There is no significant association of -174(G/C) polymorphism in the promoter sequence of IL-6 and the incidence of AMI in the examined sample of Egyptian population. Elevated levels of serum IL-6 confirmed the relationship between inflammation and the incidence of AMI.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiovascular disease (CVD) remains the major cause of death worldwide. Most CVD can be prevented by addressing risk factors. Acute myocardial infarction (AMI) is an inflammatory disorder characterized by changes in several cytokines including the interleukins (ILs). Studies are running to evaluate the genetic variation in the inflammatory system and their influence on the risk factors for CVD aiming for future prevention of this global disease. The aim of the current study was too investigate the association of -174 (G/C) IL-6 polymorphism with the incidence of AMI in a representative sector of the Egyptian population and to examine the contribution of IL-6, as a biomarker, in the pathogenesis of AMI. Genotyping of -174 (G/C) IL-6 polymorphism was done by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) while IL-6 levels were assayed by ELISA.
RESULTS
RESULTS
The genotype distribution of -174 (G/C) IL-6 gene was not significantly different between the control subjects (GG 81.7%, GC 16.3%, CC 1.9%) and the AMI patients (GG 79%, GC 19%, CC 2%).The serum levels of IL-6 were significantly elevated in the AMI patients in comparison to the control subjects (P < 0.0001).
CONCLUSIONS
CONCLUSIONS
There is no significant association of -174(G/C) polymorphism in the promoter sequence of IL-6 and the incidence of AMI in the examined sample of Egyptian population. Elevated levels of serum IL-6 confirmed the relationship between inflammation and the incidence of AMI.
Identifiants
pubmed: 34542791
doi: 10.1186/s43141-021-00243-x
pii: 10.1186/s43141-021-00243-x
pmc: PMC8452807
doi:
Types de publication
Journal Article
Langues
eng
Pagination
139Informations de copyright
© 2021. The Author(s).
Références
Coron Artery Dis. 2007 Aug;18(5):333-7
pubmed: 17627181
Open Access Maced J Med Sci. 2017 Oct 17;5(7):831-835
pubmed: 29362605
Pak J Med Sci. 2016 Jul-Aug;32(4):880-5
pubmed: 27648032
Genes Environ. 2021 Jan 12;43(1):1
pubmed: 33436103
Genet Res (Camb). 2013 Oct;95(5):138-45
pubmed: 24246088
Am Heart J. 2004 Jul;148(1):7-15
pubmed: 15215786
Metab Syndr Relat Disord. 2013 Jun;11(3):205-9
pubmed: 23461479
Br J Haematol. 2000 Apr;109(1):39-45
pubmed: 10848780
Diabetes Care. 2017 Jan;40(Suppl 1):S75-S87
pubmed: 27979896
Clin Biochem. 2010 Sep;43(13-14):1085-9
pubmed: 20493832
J Clin Pathol. 2006 Feb;59(2):211-5
pubmed: 16443741
Vascul Pharmacol. 2019 Jan;112:54-71
pubmed: 30115528
Cell Adh Migr. 2011 Jan-Feb;5(1):20-2
pubmed: 20935502
Mol Biol Rep. 2014;41(4):2281-6
pubmed: 24415302
Korean J Intern Med. 2012 Sep;27(3):327-37
pubmed: 23019398
J Mol Cell Cardiol. 1992 Jun;24(6):579-84
pubmed: 1518075
Nat Genet. 2011 Mar 06;43(4):333-8
pubmed: 21378990
Int J Cardiol. 2004 Nov;97(2):205-12
pubmed: 15458685
Trends Cardiovasc Med. 2019 Aug;29(6):363-371
pubmed: 30292470
Cancer Causes Control. 2010 Jul;21(7):1131-8
pubmed: 20333461
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2657-62
pubmed: 11116068
Balkan J Med Genet. 2013 Dec;16(2):53-8
pubmed: 24778564
Arterioscler Thromb Vasc Biol. 2002 Dec 1;22(12):2066-71
pubmed: 12482836
Tissue Antigens. 2004 Oct;64(4):492-9
pubmed: 15361128
Nephrol Dial Transplant. 2009 Sep;24(9):2847-51
pubmed: 19349293
Clin Cancer Res. 2003 Jun;9(6):2173-6
pubmed: 12796383
J Mol Med (Berl). 2002 Aug;80(8):507-13
pubmed: 12185451
Jpn Heart J. 2003 Sep;44(5):613-22
pubmed: 14587643
Biochem Pharmacol. 2009 Sep 15;78(6):539-52
pubmed: 19413999
Circulation. 2001 May 8;103(18):2260-5
pubmed: 11342474